1. Home
  2. HRMY vs KYN Comparison

HRMY vs KYN Comparison

Compare HRMY & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$42.11

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

N/A

Current Price

$14.79

Market Cap

2.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
KYN
Founded
2017
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
HRMY
KYN
Price
$42.11
$14.79
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$44.11
N/A
AVG Volume (30 Days)
603.1K
271.0K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
8.99%
EPS Growth
7.97
N/A
EPS
1.84
N/A
Revenue
$868,453,000.00
N/A
Revenue This Year
$19.75
N/A
Revenue Next Year
$12.88
N/A
P/E Ratio
$23.20
$20.75
Revenue Growth
21.51
N/A
52 Week Low
$25.52
$11.31
52 Week High
$43.49
$15.17

Technical Indicators

Market Signals
Indicator
HRMY
KYN
Relative Strength Index (RSI) 69.47 59.24
Support Level $34.87 $13.62
Resistance Level N/A $15.10
Average True Range (ATR) 1.24 0.23
MACD 0.29 0.02
Stochastic Oscillator 86.77 75.36

Price Performance

Historical Comparison
HRMY
KYN

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: